Genetesis, Inc. is a medical technology company focused on redefining the way myocardial ischemia and coronary artery disease are detected. Genetesis’ flagship product, The CardioFlux Magnetocardiograph, is an FDA cleared, non-invasive, functional biomagnetic imaging system that measures the natural magnetic fields produced by the electrical activity in the heart.

CardioFlux leverages Magnetocardiography (MCG), a 40+ year old science that has previously been constrained by technical feasibility and heavy investments. CardioFlux has overcome these barriers of the past, and its technical advancements are poised to be easily integrated into clinical workflows.

All CardioFlux scans are performed at rest, with absolutely no patient exposure to radiation or pharmaceuticals. As a 90-second scan, CardioFlux is less time-intensive and costly to patients, providers and payers facing inefficiencies with the current standard of chest pain triage.

Genetesis Founder Story:

Hear from Founder, Peeyush Shrivastava, on the inspiration behind CardioFlux and the beginnings of Genetesis.